Organon | Jotup

Inception Fertility's 2023 Annual Summit Celebrates the Patient Experience and Honors Team Members and Clinics for their Dedication to Aspiring Parents

Retrieved on:

木曜日, 3月 9, 2023

HOUSTON, March 9, 2023 /PRNewswire/ -- Inception Fertility™ (Inception), the largest provider of comprehensive fertility services in North America, announces today the winners of its 2023 Patient Experience Awards, presented at the 2023 Annual Inception Physician Summit, a gathering of Inception physicians and team members across its expansive family of brands, that celebrates their contributions to providing aspiring parents with the highest level of professional, individualized care. The 2023 Patient Experience Awards winners were part of Inception's family of brands, which includes the clinical network, The Prelude Network®.

Key Points:

The 2023 Patient Experience Awards gala recognizes the contributions and commitments of Inception family members; the annual summit brings together fertility leaders to discuss advances and research in fertility care.
The 2023 Patient Experience Awards winners were part of Inception's family of brands, which includes the clinical network, The Prelude Network ®.
The annual summit also serves as an opportunity for Inception members to collaborate on best practices for patient care, define the future of Inception, and to continue moving the industry forward through advancements in science, medicine, and individualized patient experience.
This year's awards include the Patient Experience Leader Award, CEO's Patient Experience Emerging Leader Award, Patient Experience Tenet Leaders Awards, Patient Experience Outstanding Practice Award, and the Patient Experience Legacy Award.

Organon Canada receives the Women in Governance (WiG) Parity Certification SME, further demonstrating its commitment to gender parity in the workplace

Retrieved on:

金曜日, 3月 3, 2023

The WiG Parity Certification SME is a national benchmark recognizing notable organizations for their ongoing efforts and commitments to gender parity in the workplace.

Key Points:

The WiG Parity Certification SME is a national benchmark recognizing notable organizations for their ongoing efforts and commitments to gender parity in the workplace.
"This recognition is a strong testament to our ongoing commitment to gender equity in the workplace and beyond," says Michael Casia, President and Managing Director at Organon Canada.
"At Organon Canada, our mission is to deliver impactful solutions which help to envision a better and healthier every day for everyone, with a focus on women.
To learn more about Organon Canada's vision and values as it relates to diversity, equity, inclusion and belonging, visit organon.com/Canada-en/mission-vision-values/ .

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organon & Co. - OGN

Retrieved on:

水曜日, 3月 1, 2023

NYSE, OGN, Organon & Co., Organon, News, Cryptocurrency, Private investigator

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN).

Key Points:

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN).
Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
The investigation concerns whether Organon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

Ahead of International Women's Day, Organon Canada Spotlights the Importance of Supporting Women's Equity While Highlighting the Cost of Not Investing in Their Health

Retrieved on:

月曜日, 2月 27, 2023

KIRKLAND, QC, Feb. 27, 2023 /CNW/ - For far too long, women's health issues have been underfunded, under researched and underserved.

Key Points:

KIRKLAND, QC, Feb. 27, 2023 /CNW/ - For far too long, women's health issues have been underfunded, under researched and underserved.
In fact, only 24% of women felt their physician is very knowledgeable about gynecological and reproductive health.
With Organon Canada's support and leadership, we can truly make a meaningful difference in the name of women's health.
For further insights and to view additional data from the Alberta Women's Health Foundation survey, visit albertawomenshealthfoundation.org/our-impact .

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organon & Co. - OGN

Retrieved on:

月曜日, 2月 20, 2023

NYSE, News, Organon & Co., Organon, Private investigator

NEW YORK, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN).

Key Points:

NEW YORK, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN).
Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
The investigation concerns whether Organon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

Eyenuk Welcomes Paul Praino as Chief Commercial Officer

Retrieved on:

木曜日, 2月 16, 2023

LOS ANGELES, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Eyenuk , a global artificial intelligence (AI) digital health company, and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, announced the appointment of Paul Praino as the company’s Chief Commercial Officer.

Key Points:

LOS ANGELES, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Eyenuk , a global artificial intelligence (AI) digital health company, and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, announced the appointment of Paul Praino as the company’s Chief Commercial Officer.
Praino will oversee the continued development and execution of Eyenuk’s commercial strategy during a time of significant U.S. and international growth for the company.
“As more and more healthcare organizations are turning to Eyenuk to expand access to eyesight-saving technology, I am thrilled to welcome Paul as our new CCO to lead our expansion through our next stage of growth," said Kaushal Solanki, CEO and Founder of Eyenuk.
“We are confident that his strategic approach and his experience hiring, developing, and motivating the commercial team will drive and accelerate our impact."

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2022

Retrieved on:

木曜日, 2月 16, 2023

Medical Devices, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Growth, Heist, Acquisition, Organon, GAAP, Pharmaceutical industry, Cryptocurrency

Adjusted EBITDA margin was 33.8% for the full year 2022 compared with 36.1% for the full year 2021.

Key Points:

Adjusted EBITDA margin was 33.8% for the full year 2022 compared with 36.1% for the full year 2021.
Net income from continuing operations for 2022 was $917 million, or $3.59 per diluted share, compared with $1.4 billion, or $5.31 per diluted share in 2021.
As of December 31, 2022, cash and cash equivalents were $706 million, and debt was $8.9 billion.
These items are uncertain, depend on various factors, and could be material to Organon’s results computed in accordance with GAAP.

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023

Retrieved on:

月曜日, 2月 6, 2023

Pharmaceutical, Health, Women, Consumer, OGN, ID, EST, Interest, NYSE, Webcast, Security (finance), Organon

Organon (NYSE: OGN), a global women’s healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.

Key Points:

Organon (NYSE: OGN), a global women’s healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.
Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/ .
A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.
Institutional investors and analysts interested in participating in the call must register in advance by clicking on this link: https://conferencingportals.com/event/ZGyfDfjk .

Ahead of International Women's Day, Organon Calls for Recognition of the Impacts of Underinvesting in Women's Health

Retrieved on:

月曜日, 2月 13, 2023

DUBAI, UAE, Feb. 13, 2023 /PRNewswire/ -- For far too long, women's health issues have been underfunded, under researched and underserved. Leading up to International Women's Day on March 8, Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers, and others – to consider the consequences of continuing to treat women's health as an afterthought. For the second consecutive year, the company is also providing its employees, including over 400 employees in the Middle East, North Africa, and Turkey region (MENAT), with paid time off to shine a light and speak out in service of women's health.

Key Points:

Leading up to International Women's Day on March 8, Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers, and others – to consider the consequences of continuing to treat women's health as an afterthought.
Mr. Koussa added: "The first step of advancing women's health is listening to women, to understand her needs truly.
We continue to work closely with key government stakeholders and various medical societies to educate and empower women".
Multiple research and studies across numerous areas of women's health reveal crucial and dangerous gaps that impact nearly all stages of a woman's lifer life.

Ahead of International Women's Day, Organon Calls for Recognition of the Impacts of Underinvesting in Women's Health

Retrieved on:

月曜日, 2月 13, 2023

DUBAI, UAE, Feb. 13, 2023 /PRNewswire/ -- For far too long, women's health issues have been underfunded, under researched and underserved. Leading up to International Women's Day on March 8, Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers, and others – to consider the consequences of continuing to treat women's health as an afterthought. For the second consecutive year, the company is also providing its employees, including over 400 employees in the Middle East, North Africa, and Turkey region (MENAT), with paid time off to shine a light and speak out in service of women's health.

Key Points:

Leading up to International Women's Day on March 8, Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers, and others – to consider the consequences of continuing to treat women's health as an afterthought.
Mr. Koussa added: "The first step of advancing women's health is listening to women, to understand her needs truly.
We continue to work closely with key government stakeholders and various medical societies to educate and empower women".
Multiple research and studies across numerous areas of women's health reveal crucial and dangerous gaps that impact nearly all stages of a woman's lifer life.